Impact pioneers honored for groundbreaking ideas in the fields of healthcare and nutrition

BayerThe Bayer Cares Foundation recently presented the 2018 Aspirin Social Innovation Awards to five international initiatives for their groundbreaking ideas in the fields of healthcare and nutrition. The award-winners are all impact pioneers whose concepts have the potential to bring about sustainable, systematic changes to thus improve the living conditions of hundreds of millions of people worldwide.

From 25 nominations the following four initiatives were selected by the expert jury: DeepDee (Belarus) for a smartphone-based eye screening device; SEEKEWA (Ivory Coast) for a crowdfunding investment platform for smallholders; Elixier AI (UK) for an intelligent pregnancy monitoring device; and Timless (USA) for an AI-based app to support Alzheimer’s patients. Besides these five awards, there were also one special prize: The winner of the Special China Award, the StarFarmer initiative, with its project to improve the quality of contaminated farmland soil through earthworm-based biotechnology. Each award-winner receives EUR 20,000 in prize money to further enhance the impact of their ideas. Brief summaries of the award-winning organizations:

DeepDee, Belarus: smartphone-based eye screening device

The 500 million diabetes sufferers worldwide have a very high risk of developing diabetic retinopathy, an eye disease that causes blindness if not treated quickly. The only way to prevent this is by screening the retina of diabetes patients at least twice a year. But in many cases this is impossible for financial reasons or because no eye doctor is available. DeepDee is an AI-based eye disease detection device that makes affordable mass retina screenings possible via lenses, a smartphone, and machine learning algorithms. www.deepdee.org

SEEKEWA, Ivory Coast: crowdfunding investment platform for smallholders

Some 500 million smallholders are responsible for around 75% of the food produced worldwide. These farmers could sustainably improve global food supplies and prevent hunger, but most of them live in poverty and have not got the financial resources to invest in their own farms. SEEKEWA, the first in-kind crowdfunding platform for African smallholders, uses the money provided by Internet users and businesses worldwide to buy and allocate equipment and services via a sophisticated voucher system. In this way, SEEKEWA enables a systematic boost to the productivity of these smallholder farms. www.seekewa.com

Elixir AI, UK: AI-based pregnancy monitoring device

Worldwide, there are 5 million premature births a year. With more than a million of these newborns not surviving, premature births are the main cause of newborn deaths. Premature births are most frequently caused by a simple infection the expectant mother is suffering from. But doctors face huge difficulties in detecting such an infection. Elixir AI is an intelligent, AI-based learning device for monitoring pregnancies. Through systematically measuring and using AI to evaluate straightforward parameters in expectant mothers, Elixir AI enables any risk of a premature birth to be detected at an early stage in the pregnancy so doctors can initiate treatment in good time. www.elixir.ai

Timeless, U.S.: AI-based care app for Alzheimer's patients

The world is running headlong into an Alzheimer’s crisis. By 2050, an estimated 150 million people will be living with the disease, and caring for these patients will present a massive challenge to healthcare systems worldwide. Timeless, an easy-to-use smartphone app initially invented by 15-year-old Emma Yang for her grandmother to use, helps Alzheimer’s sufferers to remember events, remain engaged, and stay connected with friends and family. Another key feature is its first-of-its-kind AI-based facial recognition technology. In this way, by supporting Alzheimer’s sufferers in various areas of their lives, Timeless helps them and their loved ones to live longer with the disease in a normal home environment. www.timeless.care

StarFarmer, China: earthworm-based soil improvement solution

In China natural disasters and flooding have resulted in nearly 100 million hectares of saline alkali farmland, and almost 20% of the country's soil has excessive heavy metal content. This results in harvest losses and some 12 million tons of contaminated wheat every year. StarFarmer’s earthworm-based biotechnology combines ancient wisdom with modern technology. This affordable and ecologically sound soil improvement solution is based on a crade-to-cradle cycle in a so-called circular economy. In this case, agricultural waste deposited on contaminated soil is converted by earthworms into a soil modifier, which then is used to neutralize the salt and heavy metal content of the soil and thus increase the nutritional value of the farmland.

The Aspirin Social Innovation Award is an international excellence prize for social-impact entrepreneurs and pioneers whose innovations help to improve healthcare or combat hunger. Since 2010, 39 organizations have been selected and supported with around EUR 650,000. Their innovations have the potential to sustainably improve the lives of billions of people. The 2019 Aspirin Social Innovation Awards will be announced next November.

Bayer Cares Foundation

As the social impact foundation of the innovation company Bayer, the Bayer Cares Foundation sees itself as initiator, promoter and partner for innovation at the interface between academia, industry and civil society. The programs are focused on people - their commitment to societal progress, their wealth of ideas in fulfilling social challenges, and those that arise in times of emergency. The foundation's funding activities are a central element of Bayer's global corporate societal engagement (CSE) of around EUR 50 million annually - with the focus on research and social innovations in healthcare and nutrition.

Most Popular Now

Preventing tumor metastasis

Researchers at the Paul Scherrer Institute, together with colleagues from the pharmaceutical company F. Hoffmann-La Roche AG, have taken an important step towards the dev...

A new drug could revolutionize the treatment of ne…

The international team of scientists from Gero Discovery LLC, the Institute of Biomedical Research of Salamanca, and Nanosyn, Inc. has found a potential drug that may pre...

Interactions discovered in cells insulating nerve …

Schwann cells form a protective sheath around nerve fibres and ensure that nerve impulses are transmitted rapidly. If these cells are missing or damaged, severe neurologi...

Breast cancer can form 'sleeper cells' after drug …

Breast cancer medicines may force some cancer cells into 'sleeper mode', allowing them to potentially come back to life years after initial treatment. These are the early...

Anniversary of the pivotal RE-LY® trial marks a de…

Boehringer Ingelheim today announces the ten-year anniversary of the RE-LY® trial publication(1-3) recognising the contribution made in the decade since by patients, heal...

Experimental validation confirms the ability of ar…

Insilico Medicine, a global leader in artificial intelligence for drug discovery, announced the publication of a paper titled, "Deep learning enables rapid identification...

AstraZeneca agrees to buy US FDA Priority Review V…

AstraZeneca announced that it has agreed to buy a US Food and Drug Administration (FDA) Priority Review Voucher (PRV) for a total cash consideration of $95m from a subsid...

Boehringer Ingelheim eExpands KRAS cancer program …

Boehringer Ingelheim and Lupin Limited (Lupin) announced a licensing, development and commercialization agreement for Lupin's MEK inhibitor compound (LNP3794) as a potent...

Pfizer invests half billion dollars to advance sta…

Pfizer announced an additional half billion dollar investment for the construction of its state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina...

The Pfizer Foundation invests in 20 organizations …

The Pfizer Foundation announced 20 grants* to help non-governmental organizations (NGOs), non-profits and social enterprises address critical health challenges related to...

FDA grants Fast Track designation for Farxiga in c…

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to delay the ...

Tagrisso approved in China as a 1st-line treatment…

AstraZeneca today announced that it has received marketing authorisation from China's National Medical Products Administration (NMPA) for Tagrisso (osimertinib) as a 1st-...